| Literature DB >> 25961072 |
Elena Franco-Robles1, Mercedes G López1.
Abstract
Previous studies have shown that fructans, a soluble dietary fiber, are beneficial to human health and offer a promising approach for the treatment of some diseases. Fructans are nonreducing carbohydrates composed of fructosyl units and terminated by a single glucose molecule. These carbohydrates may be straight or branched with varying degrees of polymerization. Additionally, fructans are resistant to hydrolysis by human digestive enzymes but can be fermented by the colonic microbiota to produce short chain fatty acids (SCFAs), metabolic by-products that possess immunomodulatory activity. The indirect role of fructans in stimulating probiotic growth is one of the mechanisms through which fructans exert their prebiotic activity and improve health or ameliorate disease. However, a more direct mechanism for fructan activity has recently been suggested; fructans may interact with immune cells in the intestinal lumen to modulate immune responses in the body. Fructans are currently being studied for their potential as "ROS scavengers" that benefit intestinal epithelial cells by improving their redox environment. In this review, we discuss recent advances in our understanding of fructans interaction with the intestinal immune system, the gut microbiota, and other components of the intestinal lumen to provide an overview of the mechanisms underlying the effects of fructans on health and disease.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25961072 PMCID: PMC4417592 DOI: 10.1155/2015/289267
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Figure 1Structural comparison of the (a) inulin from Cichorium intybus and (b) agavin from Agave spp.
Main prebiotic effects of fructans in in vitro and in vivo studies.
| Effect | Type of fructan | Dose/duration | Model | Results | Reference |
|---|---|---|---|---|---|
| Decreasing blood glucose | FOS, inulin | 8 g/d for 14 days; 10% for 4 weeks | Diabetic subjects; animal models | Significant reduction of mean fasting blood glucose levels. Improving glucose tolerance | [ |
|
| |||||
| Reduction in blood serum triacylglycerol levels | FOS, inulin | 4–34 g/d for 21–60 days; 10% for 3–5 weeks | Healthy humans; obese animal models | Significant reduction in blood serum triacylglycerol levels | [ |
|
| |||||
| Improved lipid metabolism | FOS, GOS, inulin, and agavins | 5%–10% for 21 day to 8 weeks | Obese animal models | Decrease in body weight gain. Decrease in epididymal adipose tissue, inguinal adipose tissue, and subcutaneous adipose tissue. Reducing fat-mass development | [ |
|
| |||||
| Stimulation of lactobacilli and bifidobacteria and decreasing pathogens | FOS, GOS, and inulin | 2.5–34 g/d for 14–64 days | Healthy subjects and animal models | Stimulating the growth of bifidobacteria and contributing to the suppression of potential pathogenic bacteria | [ |
|
| |||||
| Relief of constipation | Inulin, FOS, and GOS | 20–40 g/d for 19 days | Constipated humans and animal models | Inulin showing a better laxative effect than lactose and reducing functional constipation with only mild discomfort | [ |
|
| |||||
| Increased production of SCFAs and decreasing colon pH | Inulin, FOS, and agavins | 24 g/d for 5 weeks; 10% for 28 days | Healthy subjects; animal models | Significant increase of acetate, propionate, and butyrate. Significantly increasing activity of bacterial enzymes and decreasing the pH of digesta | [ |
|
| |||||
| Improving mineral uptake | Inulin, FOS, and agavins | 1–40 g/d for 9 days; 50–100 g/kg diet for 4 weeks | Male healthy adolescents; animal models | FOS stimulating fractional calcium absorption in male adolescents. A combination of different carbohydrates showing synergistic effects on intestinal Ca absorption and balance in rats | [ |
|
| |||||
| Regulated gut peptides | Inulin, FOS, and agavins | 24 g/d for 5 weeks; 10% for 5 weeks | Healthy subjects; animals models | Increasing plasma glucagon-like peptide-1 (GLP-1) concentrations and reducing ghrelin. Increasing endogenous GLP-2 production and consequently improving gut barrier functions | [ |
|
| |||||
| Reducing body weight and energy intake | Agavins | 10% for 5 weeks | Male healthy animal model |
| [ |
|
| |||||
| Growth inhibition and prevention of adhesion of pathogenic microorganisms | FOS | 170 mg/kg, 2 weeks of lactation | Breast-fed infant; cocultures of | Oligosaccharides in human milk interfering with microbial adhesion. Reduction of exotoxin A in cultures of | [ |
|
| |||||
| Reduction of oxidative stress by reducing ROS levels | FOS, agavins | 10% for 4–8 weeks | Male obese animal models | FOS reducing TBARS urine. Lipopolysaccharides reduction in plasma. Improving the redox status by reducing the malondialdehyde serum levels and protein oxidative damage | [ |
|
| |||||
| Stimulation of the immune system | FOS, GOS, and inulin | See | |||
FOS: fructooligosaccharides; GOS: galactooligosaccharides; SCFAs: short chain fatty acids.
Figure 2Induction of an immune response through gut-associated lymphoid tissue (GALT).
Figure 3Mechanism for the indirect effect of fructans on the immune system.
Effect of fructans on the immune function in healthy animal and human models.
| Effects of fructans | Dose fructan/duration | Model | Reference |
|---|---|---|---|
| ↑ DC and γδ T cells in lamina propria of the caecum and ↓ PGE2 in small intestine, colon, and caecum | 3% FOS for 12 days | Mice treated with antibiotics and conventionalized with | [ |
|
| |||
| In peripheral blood: ↑ CD4+/CD8+ ratio and ↓ B cells. In GALT: ↑ proportion of CD4+ cells and CD8+ cells, PP, and lamina propria cells and ↓ CD4+/CD8+ ratio in lamina propria | 0.87% FOS for 14 days | Adult dogs | [ |
|
| |||
| Synbiotics ↑ whole blood phagocyte activation level. | 1% FOS for 28 days | Piglets infected with | [ |
|
| |||
| ↑ counts of leucocytes, lymphocytes, neutrophils, CD2+ T cells, CD4+ T cells, CD8+ T cells, B cells, and macrophages in blood, ↑ % phagocytic activity of leucocytes and neutrophils in blood. | 3 g/d OF for 20 days | Newborn piglets | [ |
|
| |||
| ↑ ileal IgA concentration. | 2 g/d FOS and/or MOS for 14 days | Adult dogs | [ |
|
| |||
| ↓ blood neutrophils and ↑ blood lymphocytes. | 2 g FOS plus/1 g MOS for 14 days | Adult dogs | [ |
|
| |||
| ↑ rotavirus-specific IgA levels in serum and ↓ duration of a strong rotavirus-specific IgA response in faeces and % IgA and IgG positive B cell in the PP. ↑ serum rotavirus-specific IgG and Rhesus rotavirus antigen concentration in stools. | 1.25 g/L OF for 7 weeks | Mice (pups) infected with | [ |
|
| |||
| No change in protein, alb, serum Ig, secreting IgA, and IL-4 and IFN- | 6 g OF/ITFs for 28 weeks | Healthy elderly (>70 years) | [ |
|
| |||
| ↑ % CD4 and CD8 lymphocytes, ↓ phagocytic activity in granulocytes and monocytes and IL-6 mRNA expression in PBMCs. | 8 g/day FOS, 3 weeks | Nursing home elderly (77–97 years) | [ |
|
| |||
| ↑ total faecal IgA, size of PP, total IgA secretion by PP cells and IL-10 and IFN- | 0–7.5% FOS for 6 weeks | Female mice | [ |
|
| |||
| ↓ leucocyte counts, ↑ NK activity of splenocytes and peritoneal macrophage phagocytosis of | 2.5–10% FOS or OF for 6 weeks | Female mice | [ |
|
| |||
| ↑ total number of immune cells in PP, B lymphocytes in PP and T lymphocytes and CD4+/CD8+ ratio in PP in endotoxemic mice only. | 10% FOS for 16 days | Female mice healthy or endotoxemic | [ |
|
| |||
| ↓ peripheral blood lymphocyte concentration. | 1% ITFs/MOS for 4 weeks | Senior dogs | [ |
|
| |||
| ↑ total intestinal IgA, ileal and colonic polymeric Ig receptor expression, ileal IgA secretion rate, IgA response of PP cells, and % of B220+ IgA+ cells. | 5% FOS for 23–44 days | Newborn mice | [ |
|
| |||
| ↑ IL-10 and IFN- | 10% FOS-enriched ITFs for 4 weeks | Male rats | [ |
|
| |||
| ↑ NK activity. Prevention of the decrease in proportion of T cells with NK activity. | 6 g/d OF and ITFs (2 : 1 ratio) for 1 year | Elderly free-living adults (age ≤ 70 years) | [ |
|
| |||
| Improved response to some vaccine components and increased lymphocyte proliferation to influenza vaccine components. | 4.95% FOS for 183 days | Healthy adults (age ≤ 65 years) | [ |
|
| |||
| ↑ T cells, MHCII on antigen-presenting cells in spleen, MLN, and thymus, IL-2 and IL-4 in blood. | 10% FOS/ITFs for 4 months | Male rats | [ |
|
| |||
| Trend towards higher fecal sIgA. | 0.6 g (GOS/FOS)/100 mL formula for 32 weeks | Newborn non-breast-fed infants | [ |
|
| |||
| Improved response to ↑ B cells, ↓ memory cytotoxic T cells, ↑ influenza-activated lymphocytes (CD69 and CD25) and IL-6 and ↓ IL10. | 4.95% FOS for 4 weeks | Healthy adults (age ≤ 65 years) | [ |
|
| |||
| In pregnant females and pups no effect on serum IgG1, IgG2, IgA, or IgM. In colostrum and milk ↑ IgM. | 0.1% OF during lactation | Pregnant female dogs and pups | [ |
|
| |||
| ↓ severity of enterocyte sloughing. | 1% FOS or ITFs for 14 days | Puppies | [ |
|
| |||
| ↑ % CD19 (B) cells, CD3+ HLA-DR+ (activated T cells) and ↓ % ICAM−1 bearing lymphocytes and % CD3+ NK+ cells. | 9 g/d ITFs for 5 weeks | Adults smokers and nonsmokers | [ |
|
| |||
| ↑ vaccine-specific faecal IgA and plasma IgG levels, peritoneal macrophage activity, mean fluorescence intensity of MHCII+ cells in spleen, IL-12 and IFN- | 5% mix (ITFs, FOS, and OF) for 1 week | Female mice | [ |
|
| |||
| ↑ fecal sIgA. | 6 g/L GOS/FOS (9 : 1) for 26 weeks | Newborn healthy infants | [ |
|
| |||
| ↑ NK activity, and IL-10, ↓ IL-6, IL-1β, and TNF-α. | 5.5 g GOS/d for 10 weeks | Elderly (64–79 years) | [ |
|
| |||
| ↑ DCs in PP, ↑ IL-2, IL-10, and IFN-δ from spleen and MNL cells. ↓ number and proportion of T cell receptor (TCR-) αβ+CD8+ cells in spleen and CD45RA+ cells in MLN. | 5% ITFs for 4 weeks | Female rats | [ |
|
| |||
| ↓ total IgE, IgG1, IgG2, and IgG3; ↓ cow's milk protein-specific IgG1. | 8 g/L GOS/FOS for 6 months | Newborn infants at risk for allergy | [ |
|
| |||
| ↓ intestinal sIgA. | 2.51–0.42 g/kg/d mix of GOS, XOS, OF, and ITFs (3.6 : 1 : 0.4 : 5) for 12 days | Female rats induced with diphenoxylate | [ |
|
| |||
| ↓ IL-1 | 3–5% FOS for 30 days | Female mice | [ |
|
| |||
| ↓ LPS in blood and ↓ LPS-induced increases in gene expression in IL-1 | 5 g XOS, ITFs–XOS (3 : 1) for 4 weeks | Healthy volunteers | [ |
|
| |||
| ↓ serum cortisol, TNF- | 0.10% levan-type fructan for 42 days | Growing pigs | [ |
|
| |||
| ↑ fecal secretory IgA and ↓ fecal calprotectin and plasma C-reactive protein. | 5.5 g/d B-GOS (Bi2muno) for 12 weeks | Overweight adults | [ |
|
| |||
| ↑ TGF- | GOS/ITFs (dose and duration data not shown) | Healthy mice | [ |
|
| |||
| ↓ CD16/56 on natural killer T cells and ↓ IL-10 secretion, XOS and Bi-07 supplementation ↓ CD19 on B cells. | 8 g XOS or with 109 CFU Bi-07/d for 21 days | Healthy adults (25–65 years) | [ |
|
| |||
| ↑ cell-mediated immunity in terms of skin indurations and CD4+ T-lymphocyte population. | 20–60 g/kg FOS/ITFs for 12 weeks | Healthy rats | [ |
FOS: fructooligosaccharides; PGE2: prostaglandin E2; GALT: gut-associated lymphocyte tissue; CD: cluster of differentiation; PP: Peyer's patch; OF: oligofructose; MOS: mannanoligosaccharides; IgA: immunoglobulin A; IgG; immunoglobulin G; ITFs: inulin-type fructan; IL: interleukin; PMBCs: peripheral blood mononuclear cells; NK: natural killer cells; MHC II: major histocompatibility complex II; GOS: galactooligosaccharides; HLA: human leukocyte antigen; ICAM-1: intercellular adhesion molecule 1; IFN-γ: interferon gamma; DC: dendritic cell; TCR: T cell receptor; MLN: mesenteric lymph nodes; XO: xylooligosaccharides; LPS: lipopolysaccharides.